Form 8-K - Current report:
SEC Accession No. 0001193125-24-273953
Filing Date
2024-12-10
Accepted
2024-12-10 07:15:59
Documents
15
Period of Report
2024-12-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d888773d8k.htm   iXBRL 8-K 25602
2 EX-99.1 d888773dex991.htm EX-99.1 20494
6 GRAPHIC g888773g1210065754194.jpg GRAPHIC 2334
  Complete submission text file 0001193125-24-273953.txt   181930

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inab-20241210.xsd EX-101.SCH 2836
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20241210_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20241210_pre.xml EX-101.PRE 11698
17 EXTRACTED XBRL INSTANCE DOCUMENT d888773d8k_htm.xml XML 3752
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 241537128
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)